Modified Drug Regimen May Reduce Risks in Allogeneic Hematopoietic Cell Transplant Patients

episode

Cleveland Clinic Cancer Advances not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Could sofa theory help you find your ideal partner? 4 min · 23 Sep 2026 · Do you really know?

Behind The Scenes At Vogue World Milano 28 min · 23 Sep 2026 · The Run-Through with Vogue

Is end-to-end encryption really secure? 4 min · 23 Sep 2026 · Do you really know?

Do tongue scrapers actually help with bad breath? 5 min · 23 Sep 2026 · Do you really know?

Lab Notes: Have we found dark matter? 10 min · 23 Sep 2026 · The Science Show

Is it cool to have no friends? 26 min · 23 Sep 2026 · Today in Focus

Report any issue

Source

Recorded31 Mar 2022

Publisherfeeds.buzzsprout.com

Handlerec:1648285

Show notes

Betty Hamilton, MD, Interim Director of the Blood and Marrow Transplant (BMT) Program at Cleveland Clinic joins the Cancer Advances podcast to discuss research and findings that were presented at the 2021 American Society of Hematology Annual Meeting (ASH). Listen as Dr. Hamilton discusses graft-versus-host disease and the study that evaluates a new regimen.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in